Is there any evidence to support cephalexin 1 gm BID for complicated UTI (e.g. pyelonephritis), as opposed to 500 mg q6h?

Comment by InpharmD Researcher

There is currently no direct evidence comparing cephalexin 1 g twice daily with 500 mg every 6 hours for complicated urinary tract infections (cUTIs), including pyelonephritis. One retrospective cohort study found no significant difference in treatment failure between cephalexin 500 mg twice daily and 500 mg four times daily among the cUTI subgroup; however, each subgroup included only 33 patients. Prescribing information states that more severe infections may require doses up to 4 g daily in 2 to 4 equally divided doses, whereas the 2025 Infectious Diseases Society of America guideline recommends cephalexin 500 to 1,000 mg every 6 hours for cUTIs and acknowledges that evidence regarding optimal cephalexin dosing is limited. Similarly, a 2026 systematic review identified no clinical outcomes specifically supporting cephalexin 1 g twice daily for cUTIs and noted that its short half-life necessitates every-6-hour dosing to achieve pharmacokinetic/pharmacodynamic targets.
Background

The 2025 Infectious Diseases Society of America (IDSA) guidelines on complicated urinary tract infections (cUTIs) lists cephalexin 500-1,000 mg every 6 hours and notes that other regimens may be more effective. The guidelines acknowledge that previously published literature evaluating the optimal dosing strategy for cephalexin is limited. Comparative studies have generally reported inferior outcomes with oral β-lactams, including cephalexin, compared with fluoroquinolones or sulfamethoxazole-trimethoprim (TMP-SMX), even with optimized dosing. Cephalexin 1,000 mg every 6 hours has been used as an optimized oral β-lactam regimen in bacteremic cUTI. When oral β-lactams are selected, dosing should therefore be optimized and guided by isolate-specific susceptibility. [1]

A 2026 systematic review identified 17 observational studies evaluating oral beta-lactams for complicated UTIs, including pyelonephritis and bacteremic UTIs; however, it did not report a direct comparison of cephalexin 1 g twice daily versus 500 mg every 6 hours. The review defined cephalexin doses below 1 g every 6 hours as suboptimal for systemic infections and reported that cephalexin’s short half-life of 0.5 to 1.2 hours necessitates every-6-hour dosing to achieve pharmacokinetic/pharmacodynamic targets. Although one observational study used cephalexin 1 g 3 times daily and reported similar outcomes between high-dose oral beta-lactams and fluoroquinolones or trimethoprim/sulfamethoxazole, the review presented no clinical outcomes specifically supporting cephalexin 1 g twice daily for complicated urinary tract infections. [2]

Background References: [1] Trautner BW, Cortés-Penfield NW, Gupta K, et al. Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections-Selection of Antibiotic Therapy for Complicated Urinary Tract Infections. Clin Infect Dis. 2026;82(Supplement_3):i36-i67. doi:10.1093/cid/ciaf460
[2] Kunz Coyne AJ, Bouchard J, Durham SH, et al. Oral β-lactams for complicated urinary tract infections: a systematic review and point-counterpoint comparison with trimethoprim/sulfamethoxazole and fluoroquinolones. Pharmacotherapy. 2026;46(3):e70118. doi:10.1002/phar.70118
Relevant Prescribing Information

Dosage and administration

Adults and Pediatric Patients at Least 15 Years of Age
The usual dose is 250 mg every 6 hours but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 to 14 days. For more severe infections larger doses of oral cephalexin may be needed, up to 4 grams in two to four equally divided doses. [3]

Relevant Prescribing Information References: [3] Cephalexin tablet. Prescribing information. Teva Pharmaceuticals USA, Inc.; 2023.
Literature Review

A search of the published medical literature revealed 1 study investigating the researchable question:

Is there any evidence to support cephalexin 1 gm BID for complicated UTI (e.g. pyelonephritis), as opposed to 500 mg q6h?

Level of evidence

C - Multiple studies with limitations or conflicting results  Read more→


Please see Table 1 for your response.

Cephalexin Twice Daily Versus Four Times Daily for the Treatment of Urinary Tract Infections Diagnosed in the Emergency Department
Design

Single-center, retrospective cohort study

N= 214
Objective To compare the rates of treatment failure between patients prescribed cephalexin twice daily (BID) versus four times daily (QID) for the management of uncomplicated urinary tract infections (uUTIs) and complicated urinary tract infections (cUTIs) once discharged from the emergency department (ED)
Study Groups

Cephalexin BID (n= 107)

Cephalexin QID (n= 107)
Inclusion Criteria Patients ≥18 years old, discharged from the ED with a diagnosis of UTI, prescribed within 72 hours cephalexin 500 mg BID or QID for a duration of 5, 7, or 10 days, and a urine culture positive for Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis susceptible to cefazolin
Exclusion Criteria Creatinine clearance (CrCl) <30 mL/min, known pregnancy, UTI treatment within the previous 30 days, asymptomatic bacteriuria, or current antibiotic prescriptions for chronic UTI prophylaxis
Methods Patients were prescribed cephalexin 500 mg twice or four times daily, and monitored for treatment failure (defined as return to the ED or outpatient clinic with similar or worsening UTI symptoms or change in antibiotic therapy within 30 days). Patient data were collected from electronic medical records. Subgroup analyses were performed for both uUTI and cUTIs.
Duration July 31st, 2016 to July 31st, 2023
Outcome Measures

Primary: Treatment failure

Secondary: Clostridium difficile infection (CDI) within 30 days, reported antibiotic side effects within 7 days of treatment initiation, uUTI and cUTI subgroup analyses
Baseline Characteristics   Cephalexin BID (n= 107) Cephalexin QID (n= 107) p-value
Age, median (IQR), years  56.0 [38.5-71.0] 58.0 [41.0-75.5] 0.351
Female 98 (91.6%) 90 (84.1%) 0.094

Race

Caucasian

Black

Asian

Hispanic

 

59 (55.1%)

42 (39.3%)

3 (2.8%)

3 (2.8%)

 

51 (47.7%)

51 (47.7%)

0 (0%)

5 (4.7%)

 

0.274

0.215

0.246

0.721
Weight, median (IQR), kg 69.6 [61.2–83.9] 72.6 [61.2–93.0] 0.443
Scr, median (IQR), mg/dL 0.8 [0.7–1.1] 0.8 [0.7–1.1] 0.957
CrCl, median (IQR), mL/min 80.0 [60.0–111.0] 84.5 [59.0–128.0] 0.508
Received IV antibiotics 51 (47.7%) 54 (50.5%) 0.682
Type 2 Diabetes Mellitus 26 (24.3%) 32 (29.9%) 0.356
Chronic Indwelling Catheter 3 (2.8%) 8 (7.5%) 0.122
Urologic abnormality 24 (22.4%) 26 (24.3%) 0.747

Type of UTI

uUTI

cUTI

 

74 (69.2%)

33 (30.8%)

 

74 (69.2%)

33 (30.8%)

-

 

 

Total Duration of Therapy

5 days

7 days

10 days

 

11 (10.3%)

76 (71.0%) 

20 (18.7%) 

 

15 (14.0%)

75 (70.1%)

17 (15.9%)

 

0.403

0.881

0.588

Organism present

Escherichia coli

Klebsiella pneumoniae

Proteus mirabilis 

 

81 (75.7%)

25 (23.4%) 

2 (1.9%) 

 

86 (80.4%)

23 (21.5%)

3 (2.8%)

 

0.409

0.743

>0.99
Results   Cephalexin BID (n= 107) Cephalexin QID (n= 107) p-value
Treatment Failure 20 (18.7%) 16 (15.0%) 0.465
CDI within 30 days 0 (0.0%) 1 (1.0%) >0.99
Side effects within 7 days 3 (2.8%) 6 (5.6%) 0.498
No significant difference in treatment failure between BID and QID dosing was observed for uUTI or cUTI (14.9% vs 8.1%, p= 0.197; 27.3% vs 30.3%, p= 0.786, respectively).
Adverse Events Reported side effects within 7 days included nausea, vomiting, diarrhea, yeast infection, rash, and hives. There were no significant differences in adverse events between the BID and QID dosing groups.
Study Author Conclusions For patients with UTIs, there was no statistically significant difference in treatment failure rates between patients prescribed cephalexin twice daily versus four times daily. These findings suggest cephalexin dosed twice daily may be a reasonable option for the outpatient management of UTIs diagnosed in the ED, thus increasing adherence and decreasing cost without statistically compromising effectiveness.
Critique The study's retrospective, single-center design may limit generalizability. The small sample size and reliance on accurate EMR documentation are potential limitations. However, the study's strength lies in its manual review of patient records and inclusion of a well-defined patient population, providing real-world applicability. Further studies are needed to confirm findings and explore cephalexin's role in cUTIs.

 

Table 1 References:
[4] Rath A, Morrisette T, Hamby A, Burgoon R, Billups K. Cephalexin twice daily versus four times daily for the treatment of urinary tract infections diagnosed in the emergency department. Am J Emerg Med. 2025;93:80-85. doi:10.1016/j.ajem.2025.03.058